Membrane functional antibodies : depleting, blocking, neutralizing, agonist and antagonist

CD2, the missed opportunity for monoclonal antibody therapy?
SYnAbs unique therapeutic rat monoclonal antibodies targeting CD2 giving birth to Siplizumab and LO-CD2b for T cell depletion. Unique DNA, syngeneic cell immunization strategies to generate monoclonals against transmembrane proteins.
Anti-CD25 therapeutic monoclonal antibody strategies
SYnabs unique anti-CD25 anti-IL2R therapeutic antibody has shown great promise in clinical trials. SYnAbs antagonist anti-IL2Ra/Tac depletes Tregs for GvHD and cancer treatments.

Therapeutic targets of the complement system
The Complement System and its druggable targets by antibodies: C3aR, C5aR GPCR membrane receptors, C3, C4, C5 ligands
Monoclonal antibodies to human CD cell surface antigens
SYnAbs generates innovative functional monoclonals against clusters of differentiation markers, IgG superfamily, and C-type lectin-like receptors (CLRs). Discover how SYnAbs generate Siplizumab anti-human CD2a antibody and other transmembrane effector monoclonals.

Functional antibodies: B-cell depleting antibodies
To address all B cell depletion needs, SYnAbs has developed monoclonal antibody references, which exhibit the ability to deplete murine or rat B cells in vivo, providing a valuable research tool for its biotech and pharma partners.
Surrogate Antibodies & Therapeutic Monoclonals: Humans Mimicking Animals
SYnabs develops surrogate antibodies for preclinical evaluation of therapeutic antibody candidates in mouse, rat, and guinea pig species.

TRAIL, the new Grail?
TRAIL and TRAIL receptors (tumor-necrosis-factor related apoptosis-inducing ligand) SYnabs unique antibodies
IL1RAP, a new biomarker of interest for cancer targeting
735. 735 autopsy reports. Report after report, the conviction of Stephen was growing. What he was observing could not have happened by chance. This time, he was sure. A pattern was emerging. His hypothesis was finally confirmed. His father James had been a successful surgeon, founder of the modern scientific pathology, but his discovery could make him even more famous. The impact of what he had in front of him was far greater. He picked up his stylograph, look at the date on the

"Anta"​, "Block"​, "Neutra"​...but Who Are They?
They are sometimes qualified as an antagonist, sometimes as an agonist. Sometimes named inductive, sometimes repressive, sometimes blocking, or sometimes neutralizing. But always called antibodies. Have you ever guessed what it was about? Yes, that’s them, the biologically active antibodies.
SYnabs generates Cell-adhesion molecules (CAMs) antibodies: cadherin antibodies, selection antibodies, integrin antibodies, Ig-like CAM

Show more